Literature DB >> 32232478

Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma.

Yana Pikman1,2, Amy Saur Conway1, Amanda L Robichaud1, Samuel Kitara1, Alanna J Church3, Alyssa L Kennedy1,2, Lewis B Silverman1,2, Amy L Billett1,2, David M Weinstock4, Marian H Harris3, Kimberly Stegmaier1,2,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32232478      PMCID： PMC7160286          DOI： 10.1182/bloodadvances.2019001256

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  17 in total

1.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.

Authors:  Christopher J Sneeringer; Margaret Porter Scott; Kevin W Kuntz; Sarah K Knutson; Roy M Pollock; Victoria M Richon; Robert A Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

2.  Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.

Authors:  Yana Pikman; Gabriela Alexe; Giovanni Roti; Amy Saur Conway; Andrew Furman; Emily S Lee; Andrew E Place; Sunkyu Kim; Chitra Saran; Rebecca Modiste; David M Weinstock; Marian Harris; Andrew L Kung; Lewis B Silverman; Kimberly Stegmaier
Journal:  Clin Cancer Res       Date:  2016-11-09       Impact factor: 12.531

3.  Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.

Authors:  Sarah K Knutson; Satoshi Kawano; Yukinori Minoshima; Natalie M Warholic; Kuan-Chun Huang; Yonghong Xiao; Tadashi Kadowaki; Mai Uesugi; Galina Kuznetsov; Namita Kumar; Tim J Wigle; Christine R Klaus; Christina J Allain; Alejandra Raimondi; Nigel J Waters; Jesse J Smith; Margaret Porter-Scott; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Toshimitsu Uenaka; Roy M Pollock; Kevin W Kuntz; Akira Yokoi; Heike Keilhack
Journal:  Mol Cancer Ther       Date:  2014-02-21       Impact factor: 6.261

4.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

Authors:  Sarah K Knutson; Tim J Wigle; Natalie M Warholic; Christopher J Sneeringer; Christina J Allain; Christine R Klaus; Joelle D Sacks; Alejandra Raimondi; Christina R Majer; Jeffrey Song; Margaret Porter Scott; Lei Jin; Jesse J Smith; Edward J Olhava; Richard Chesworth; Mikel P Moyer; Victoria M Richon; Robert A Copeland; Heike Keilhack; Roy M Pollock; Kevin W Kuntz
Journal:  Nat Chem Biol       Date:  2012-09-30       Impact factor: 15.040

5.  The Genetic Basis of Hepatosplenic T-cell Lymphoma.

Authors:  Matthew McKinney; Andrea B Moffitt; Philippe Gaulard; Marion Travert; Laurence De Leval; Alina Nicolae; Mark Raffeld; Elaine S Jaffe; Stefania Pittaluga; Liqiang Xi; Tayla Heavican; Javeed Iqbal; Karim Belhadj; Marie Helene Delfau-Larue; Virginie Fataccioli; Magdalena B Czader; Izidore S Lossos; Jennifer R Chapman-Fredricks; Kristy L Richards; Yuri Fedoriw; Sarah L Ondrejka; Eric D Hsi; Lawrence Low; Dennis Weisenburger; Wing C Chan; Neha Mehta-Shah; Steven Horwitz; Leon Bernal-Mizrachi; Christopher R Flowers; Anne W Beaven; Mayur Parihar; Lucile Baseggio; Marie Parrens; Anne Moreau; Pierre Sujobert; Monika Pilichowska; Andrew M Evens; Amy Chadburn; Rex K H Au-Yeung; Gopesh Srivastava; William W L Choi; John R Goodlad; Igor Aurer; Sandra Basic-Kinda; Randy D Gascoyne; Nicholas S Davis; Guojie Li; Jenny Zhang; Deepthi Rajagopalan; Anupama Reddy; Cassandra Love; Shawn Levy; Yuan Zhuang; Jyotishka Datta; David B Dunson; Sandeep S Davé
Journal:  Cancer Discov       Date:  2017-01-25       Impact factor: 39.397

6.  Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets.

Authors:  Marion Travert; Yenlin Huang; Laurence de Leval; Nadine Martin-Garcia; Marie-Helene Delfau-Larue; Françoise Berger; Jacques Bosq; Josette Brière; Jean Soulier; Elizabeth Macintyre; Teresa Marafioti; Aurélien de Reyniès; Philippe Gaulard
Journal:  Blood       Date:  2012-04-17       Impact factor: 22.113

Review 7.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Authors:  Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Herve Tilly; Christian Bastard; Regis Angonin; Eric Deconinck; Frederic Charlotte; Veronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-Francois Emile; Beatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

8.  EZH2 mutations are frequent and represent an early event in follicular lymphoma.

Authors:  Csaba Bödör; Vera Grossmann; Nikolay Popov; Jessica Okosun; Ciarán O'Riain; King Tan; Jacek Marzec; Shamzah Araf; Jun Wang; Abigail M Lee; Andrew Clear; Silvia Montoto; Janet Matthews; Sameena Iqbal; Hajnalka Rajnai; Andreas Rosenwald; German Ott; Elias Campo; Lisa M Rimsza; Erlend B Smeland; Wing C Chan; Rita M Braziel; Louis M Staudt; George Wright; T Andrew Lister; Olivier Elemento; Robert Hills; John G Gribben; Claude Chelala; András Matolcsy; Alexander Kohlmann; Torsten Haferlach; Randy D Gascoyne; Jude Fitzgibbon
Journal:  Blood       Date:  2013-09-19       Impact factor: 22.113

9.  Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.

Authors:  Ryan D Morin; Maria Mendez-Lago; Andrew J Mungall; Rodrigo Goya; Karen L Mungall; Richard D Corbett; Nathalie A Johnson; Tesa M Severson; Readman Chiu; Matthew Field; Shaun Jackman; Martin Krzywinski; David W Scott; Diane L Trinh; Jessica Tamura-Wells; Sa Li; Marlo R Firme; Sanja Rogic; Malachi Griffith; Susanna Chan; Oleksandr Yakovenko; Irmtraud M Meyer; Eric Y Zhao; Duane Smailus; Michelle Moksa; Suganthi Chittaranjan; Lisa Rimsza; Angela Brooks-Wilson; John J Spinelli; Susana Ben-Neriah; Barbara Meissner; Bruce Woolcock; Merrill Boyle; Helen McDonald; Angela Tam; Yongjun Zhao; Allen Delaney; Thomas Zeng; Kane Tse; Yaron Butterfield; Inanç Birol; Rob Holt; Jacqueline Schein; Douglas E Horsman; Richard Moore; Steven J M Jones; Joseph M Connors; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nature       Date:  2011-07-27       Impact factor: 49.962

10.  Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Authors:  Ryan D Morin; Nathalie A Johnson; Tesa M Severson; Andrew J Mungall; Jianghong An; Rodrigo Goya; Jessica E Paul; Merrill Boyle; Bruce W Woolcock; Florian Kuchenbauer; Damian Yap; R Keith Humphries; Obi L Griffith; Sohrab Shah; Henry Zhu; Michelle Kimbara; Pavel Shashkin; Jean F Charlot; Marianna Tcherpakov; Richard Corbett; Angela Tam; Richard Varhol; Duane Smailus; Michelle Moksa; Yongjun Zhao; Allen Delaney; Hong Qian; Inanc Birol; Jacqueline Schein; Richard Moore; Robert Holt; Doug E Horsman; Joseph M Connors; Steven Jones; Samuel Aparicio; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nat Genet       Date:  2010-01-17       Impact factor: 38.330
View more
  1 in total

1.  Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.

Authors:  Zachary D Epstein-Peterson; Steven M Horwitz
Journal:  Semin Hematol       Date:  2021-03-03       Impact factor: 3.851
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.